Clicky

Aadi Biosciences, Inc.(AADI)

Description: Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARRO (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.


Keywords: Cancer Biopharmaceutical Biology Disease Oncology Tumor Drug Delivery Antineoplastic Drugs Signal Transduction mTOR Mtor Inhibitors

Home Page: aadibio.com

AADI Technical Analysis

17383 Sunset Boulevard
Pacific Palisades, CA 90272
United States
Phone: 424 473 8055


Officers

Name Title
Dr. Neil P. Desai Ph.D. Founder, Pres, CEO, Sec. & Director
Mr. Scott M. Giacobello CPA CFO & Treasurer
Mr. Brendan P. Delaney M.B.A. Chief Operating Officer
Ms. Marcy Graham SVP of Investor Relations & Corp. Communications
Mr. Stephen M. Rodin J.D. Sr. VP of Legal & Gen. Counsel
Mr. Raymond G. Steitz Sr. VP of HR & Chief HR Officer
Dr. Loretta M. Itri F.A.C.P., M.D. Chief Medical Officer
Mr. Bryan Ball Chief Quality Officer & Sr. VP of Manufacturing Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 2.5859
Price-to-Book MRQ: 1.8927
Price-to-Sales TTM: 28.1934
IPO Date: 2017-08-08
Fiscal Year End: December
Full Time Employees: 76
Back to stocks